Ajanta Pharma Q1 FY27 Results

Ajanta Pharma's Revenue from Operations reached ₹1,626 crore, marking a 25% year-on-year increase. Profit After Tax (PAT) saw a significant jump of 31% to ₹334 crore.

Reader Takeaway: Strong US and India growth offsets Asian market decline; dividend boost for shareholders.

What just happened

Ajanta Pharma announced its financial results for the first quarter of FY 2027. Revenue from operations stood at ₹1,626 crore, up 25% year-on-year from ₹1,303 crore in Q1 FY 2026. Profit After Tax (PAT) grew by 31% to ₹334 crore, compared to ₹255 crore in the prior year's first quarter. Adjusted EBITDA also increased by 21% to ₹454 crore.

Why this matters

These results indicate robust growth for Ajanta Pharma, driven by key markets like the US and India. The PAT growth outpaces revenue growth, suggesting improved margins. The declaration of an interim dividend provides a direct return to shareholders.

The backstory

The company has been focusing on expanding its presence in key international markets, particularly the US, and strengthening its domestic branded generics business. R&D investments have been maintained to support future product launches.

What changes now

Ajanta Pharma has declared a first interim dividend of ₹32 per share, with a payout of ₹400 crore. The record date is set for 5 August 2026, and payment will be made on or after 18 August 2026. This move rewards shareholders and signals financial health.

Risks to watch

The company highlighted a 16% decline in the Asian market segment, attributing it to ongoing geopolitical issues, specifically citing war. Additionally, the financial impact of income tax search operations conducted in August 2025 remains uncertain as block period returns have been filed.

Peer comparison

(No peer comparison data available in the filing.)

Context metrics (time-bound)

• US Market: 51 ANDAs commercialized, with 2 new launches in Q1 FY27. 17 products are awaiting approval.
• India Business: Branded generic performance exceeded the Indian Pharmaceutical Market (IPM) growth.
• R&D Investment: ₹66 crore for the quarter.
• Return on Capital Employed (ROCE): 37%.

What to track next

Investors will be monitoring the performance in the Asian market and any potential outcomes from the income tax investigations. Continued strong growth in the US and Indian markets will be crucial.